Overview

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.

Phase:

Phase 2

Details

Lead Sponsor:

R-Pharm

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Epothilones
Paclitaxel